BofA raised the firm’s price target on Humana (HUM) to $210 from $196 and keeps a Neutral rating on the shares. The firm raised price targets for several managed care names, citing higher multiples after CMS finalized Medicare Advantage rates for 2027, as the rule provides visibility on 2027 rates. The net update of 2.48% increases in rates is above the high end of the 1%-2% improvement versus the proposal that the market was expecting, the analyst tells investors.

Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions

Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on HUM:

Disclaimer & DisclosureReport an Issue

Humana price target raised to $227 from $206 at Wells Fargo

UnitedHealth (UNH) or Humana (HUM): Which Stock Is the Better Buy After CMS’ Surprise Rate Hike

Closing Bell Movers: Health insurers rise on higher Medicare rate hike

UnitedHealth (UNH), Humana (HUM) Stocks Soar after CMS Finalizes 2027 Medicare Advantage Rate Hike

HUM, UNH, CVS: Healthcare Stocks Soar on 2.48% Medicare Rate Increase